Blueprint Medicines (BPMC) Tops Q1 EPS by 11c

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.79), $0.11 better than the analyst estimate of ($1.90). Revenue for the quarter came in at $62.73 million versus the consensus estimate of $38.96 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Adecoagro S.A. (AGRO) Misses Q2 EPS by 63c
• Erasca, Inc. (ERAS) Misses Q2 EPS by 3c
• Immunome, Inc. (IMNM) Reports Q2 Loss of $0.65